Skip to Content

Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at ACC's 60th Annual Scientific Session



CARLSBAD, Calif., March 29, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:


Data from Two Mipomersen Phase 3 Trials presented at ACC





Tuesday, April 05, 2011 at 1:00 p.m. ET / 10:00 a.m. PT









Live on the Internet.  Simply log onto our Web site listed above.





Kristina Lemonidis



Director, Corporate Communications



(760) 603-2490





Amy Blackley, Ph.D.



Assistant Director, Corporate Communications



(760) 603-2772



If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.

Web Site:

Posted: March 2011

View comments